Global PEGylated Drugs Market, By Molecule (Protein, FAB’ Fragment, Enzyme and Aptamer), Type (Interferons, Colony Stimulating Factors, Monoclonal Antibodies (mAbs), Other Types), Disease Indication (Gastrointestinal Disorders, Cancer, Multiple Sclerosis, Hepatitis, Other Disease Indications), Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others), Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global PEGylated Drugs Market
PEGylated drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of USD 8,358.17 million and grow at a CAGR of 5.48% in the above-mentioned forecast period. Increase in research and development spending drives the PEGylated drugs market.
PEGylation is a type of process which is referred as covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules. It is a very promising technique which helps in increasing the therapeutic efficacy of medicines in clinical settings. Numerous PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.
Rising growth in biologics sector to propel the PEGylated drugs is the vital factor escalating the market growth, also rise in the adoption of protein-based drugs over non-protein-based drugs, increasing protein’s stability in the drugs, increased prevalence rate of lifestyle diseases, rising occurrence of cancer, rising spending on the healthcare expenditures due to increased disposable income and rising number of hospitals and clinics all over the globe are the major factors among others driving the PEGylated drugs market. Moreover, increasing opportunities in emerging markets and rising top-selling biologics drugs going off–patent in the near future will further create new opportunities for PEGylated drugs market in the forecasted period of 2021-2028.
However, rising adverse reactions associated with PEGylated drugs and drug recalls are the major factors among others which will obstruct the market growth, and will further challenge the growth of PEGylated drugs market in the forecast period mentioned above.
This PEGylated drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on PEGylated drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
PEGylated Drugs Market Scope and Market Size
PEGylated drugs market is segmented on the basis of molecule, type, and disease indication, application and sales channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of molecule, the PEGylated drugs market is segmented into protein, FAB’ fragment, enzyme and aptamer.
- Based on type, the PEGylated drugs market is segmented into interferons, colony stimulating factors, monoclonal antibodies (mAbs) and other types.
- Based on disease indication, the PEGylated drugs market is segmented into gastrointestinal disorders, cancer, multiple sclerosis, hepatitis and other disease indications.
- Based on application, the PEGylated drugs market is segmented into cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others.
- The PEGylated drugs market is also segmented on the basis of sales channel into hospital pharmacy, online provider and retail pharmacy.
Global PEGylated Drugs Market Country Level Analysis
PEGylated drugs market is analysed and market size insights and trends are provided by molecule, type, disease indication, application and sales channel as referenced above.
The countries covered in the PEGylated drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the PEGylated drugs market due to rising prevalence of cancer along with advancements in the field of cancer research and rising usage of advanced drug delivery systems with PEGylation technology in this region. Europe is the second largest region in terms of growth in PEGylated drugs market due to increasing efforts by the government to reduce chronic disease burden due to the rising occurrence of cancer in the region.
The country section of the PEGylated drugs market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
PEGylated drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for PEGylated drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the PEGylated drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and PEGylated Drugs Market Share Analysis
PEGylated drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to PEGylated drugs market.
The major players covered in the PEGylated drugs market report are Enzon Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Affymax, Inc, Novo Nordisk A/S, Biogen, Amgen Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc, AstraZeneca, Nektar, Leadiant Biosciences, Inc, UCB S.A., Horizon Therapeutics plc, Eiger BioPharmaceuticals, Halozyme, Inc, Biocad, PharmaEssentia Corporation, Novo Nordisk A/S and Bayer AG among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-